Jian Zhou1, Hui-Chuan Sun1, Zheng Wang1, Wen-Ming Cong2, Jian-Hua Wang3, Meng-Su Zeng4, Jia-Mei Yang5, Ping Bie6, Lian-Xin Liu7, Tian-Fu Wen8, Guo-Hong Han9, Mao-Qiang Wang10, Rui-Bao Liu11, Li-Gong Lu12, Zheng-Gang Ren1, Min-Shan Chen13, Zhao-Chong Zeng14, Ping Liang15, Chang-Hong Liang16, Min Chen17, Fu-Hua Yan18, Wen-Ping Wang19, Yuan Ji20, Wen-Wu Cheng21, Chao-Liu Dai22, Wei-Dong Jia23, Ya-Ming Li24, Ye-Xiong Li25, Jun Liang26, Tian-Shu Liu27, Guo-Yue Lv28, Yi-Lei Mao29, Wei-Xin Ren30, Hong-Cheng Shi31, Wen-Tao Wang8, Xiao-Ying Wang1, Bao-Cai Xing32, Jian-Ming Xu33, Jian-Yong Yang34, Ye-Fa Yang35, Sheng-Long Ye1, Zheng-Yu Yin36, Bo-Heng Zhang1, Shui-Jun Zhang37, Wei-Ping Zhou5, Ji-Ye Zhu38, Rong Liu3, Ying-Hong Shi1, Yong-Sheng Xiao1, Zhi Dai1, Gao-Jun Teng39, Jian-Qiang Cai40, Wei-Lin Wang41, Jia-Hong Dong42, Qiang Li43, Feng Shen5, Shu-Kui Qin44, Jia Fan1. 1. Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China. 2. Department of Pathology, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. 3. Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. 4. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. 5. Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. 6. Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China. 7. Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China. 8. Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China. 9. Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. 10. Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, China. 11. Department of Interventional Radiology, the Tumor Hospital of Harbin Medical University, Harbin, China. 12. Department of Interventional Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 13. Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. 14. Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. 15. Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China. 16. Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 17. Editorial Department of Chinese Journal of Digestive Surgery, Chongqing, China. 18. Department of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. 19. Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China. 20. Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. 21. Department of integrated treatment, Tumor Hospital of Fudan University, Shanghai, China. 22. Department of Hepatobiliary and Spleenary Surgery, the Affiliated Shengjing Hospital, China Medical University, Shenyang, China. 23. Department of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China. 24. Department of Nuclear Medicine, the First Hospital of China Medical University, Shenyang, China. 25. Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 26. Department of Oncology, Peking University International Hospital, Beijing, China. 27. Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. 28. Department of General Surgery, the First Hospital of Jilin University, Jilin, China. 29. Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China. 30. Department of Interventional Radiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. 31. Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. 32. Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China. 33. Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China. 34. Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 35. Department of Hepatic Surgery and Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. 36. Department of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China. 37. Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 38. Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China. 39. Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China. 40. Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 41. Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. 42. Department of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China. 43. Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 44. Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) (about 85-90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people. SUMMARY: This guideline presents official recommendations of the National Health and Family Planning Commission of the People's Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China. The guideline was written by more than 50 experts in the field of HCC in China (including liver surgeons, medical oncologists, hepatologists, interventional radiologists, and diagnostic radiologists) on the basis of recent evidence and expert opinions, balance of benefits and harms, cost-benefit strategies, and other clinical considerations. KEY MESSAGES: The guideline presents the Chinese staging system, and recommendations regarding patients with HCC in China to ensure optimum patient outcomes.
BACKGROUND: Hepatocellular carcinoma (HCC) (about 85-90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people. SUMMARY: This guideline presents official recommendations of the National Health and Family Planning Commission of the People's Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China. The guideline was written by more than 50 experts in the field of HCC in China (including liver surgeons, medical oncologists, hepatologists, interventional radiologists, and diagnostic radiologists) on the basis of recent evidence and expert opinions, balance of benefits and harms, cost-benefit strategies, and other clinical considerations. KEY MESSAGES: The guideline presents the Chinese staging system, and recommendations regarding patients with HCC in China to ensure optimum patient outcomes.
Authors: T Pressiani; C Boni; L Rimassa; R Labianca; S Fagiuoli; S Salvagni; D Ferrari; E Cortesi; C Porta; C Mucciarini; L Latini; C Carnaghi; M Banzi; S Fanello; M De Giorgio; F R Lutman; G Torzilli; M A Tommasini; R Ceriani; G Covini; M C Tronconi; L Giordano; N Locopo; S Naimo; A Santoro Journal: Ann Oncol Date: 2012-10-05 Impact factor: 32.976
Authors: J G D'Haese; J Neumann; M Weniger; S Pratschke; B Björnsson; V Ardiles; W Chapman; R Hernandez-Alejandro; O Soubrane; R Robles-Campos; M Stojanovic; R Dalla Valle; A C Y Chan; M Coenen; M Guba; J Werner; E Schadde; M K Angele Journal: Ann Surg Oncol Date: 2015-12-08 Impact factor: 5.344
Authors: Chung Mau Lo; Chi Leung Liu; See Ching Chan; Chi Ming Lam; Ronnie T P Poon; Irene O L Ng; Sheung Tat Fan; John Wong Journal: Ann Surg Date: 2007-06 Impact factor: 12.969